Clarkson Optometry, Inc | |
217 Clarkson Rd, Ellisville, MO 63011-2219 | |
(636) 200-4393 | |
(636) 200-4020 |
Full Name | Clarkson Optometry, Inc |
---|---|
Type | Facility |
Speciality | Optometrist |
Location | 217 Clarkson Rd, Ellisville, Missouri |
Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1497155345 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
152W00000X | Optometrist | T03019 (Missouri) | Primary |
Provider Name | Lisa A Durham |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1629074620 PECOS PAC ID: 8628035318 Enrollment ID: I20041214000897 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Kayce A Strohmeyer |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1871643718 PECOS PAC ID: 2365490877 Enrollment ID: I20050111000393 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Amanda J Bissell |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1336145481 PECOS PAC ID: 0648221655 Enrollment ID: I20050208000262 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Robert W Rottler |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1376549378 PECOS PAC ID: 2466403274 Enrollment ID: I20050209000045 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Laura M Hegyi |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1689643249 PECOS PAC ID: 9335191428 Enrollment ID: I20050217000100 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Janet H Graf |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1972509883 PECOS PAC ID: 3779537337 Enrollment ID: I20050307000219 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Amber L Mccormick Gossage |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1013908938 PECOS PAC ID: 5496785958 Enrollment ID: I20050816000131 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Scott E Smalley |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1174534879 PECOS PAC ID: 1850324450 Enrollment ID: I20050914000762 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Cinnamon Marie Langford |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1558375865 PECOS PAC ID: 8527091701 Enrollment ID: I20050917000207 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Lucias D Meyer |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1720032600 PECOS PAC ID: 0941235576 Enrollment ID: I20051003000028 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Janet Collier |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1982606695 PECOS PAC ID: 2567487846 Enrollment ID: I20051006000519 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Diane M Jessen |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1063573400 PECOS PAC ID: 8426074329 Enrollment ID: I20051020000285 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Tiffany J Johnson |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1255466728 PECOS PAC ID: 2961429121 Enrollment ID: I20051027000055 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Jennifer Klinger |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1114923109 PECOS PAC ID: 2163320789 Enrollment ID: I20051115000700 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Sarah D Hubbard |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1063467025 PECOS PAC ID: 8325050941 Enrollment ID: I20060626000043 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Sara T Strasser |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1407824139 PECOS PAC ID: 8022011279 Enrollment ID: I20060809000123 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Emma M Schafers-karl |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1558389270 PECOS PAC ID: 8921005646 Enrollment ID: I20061023000048 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Cathy L Phillips |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1326016601 PECOS PAC ID: 3678573946 Enrollment ID: I20070110000466 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Lianne L Innes |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1780745331 PECOS PAC ID: 7810998549 Enrollment ID: I20070124000299 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Stacy M Bell Simmons |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1154379535 PECOS PAC ID: 0547363616 Enrollment ID: I20070309000202 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Kathleen J Boland |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1093822389 PECOS PAC ID: 7810090529 Enrollment ID: I20070319000473 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Blaire S Obrien |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1548467798 PECOS PAC ID: 8729189170 Enrollment ID: I20070730000091 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Amber L Koester |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1376696708 PECOS PAC ID: 6709823040 Enrollment ID: I20080314000146 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | William F Kiefer |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1588627400 PECOS PAC ID: 8729164967 Enrollment ID: I20080327000587 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Sara Day |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1811090830 PECOS PAC ID: 9537246590 Enrollment ID: I20080402000105 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Mindy B Rennard |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1851304240 PECOS PAC ID: 7416035308 Enrollment ID: I20080417000206 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Joel T Hubbard |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1801952734 PECOS PAC ID: 3678643285 Enrollment ID: I20080609000048 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Cody G Tubbs |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1831353861 PECOS PAC ID: 5193891299 Enrollment ID: I20080912000462 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Melissa S Schneider |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1477716264 PECOS PAC ID: 8729154844 Enrollment ID: I20080912000600 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Michael J Katich |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1669449765 PECOS PAC ID: 8628116746 Enrollment ID: I20091111000060 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Deanne M Wolk |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1922236678 PECOS PAC ID: 1254471725 Enrollment ID: I20091214000319 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Aaron M Brewer |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1033306709 PECOS PAC ID: 3870680119 Enrollment ID: I20100623000465 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Justin T Wilkinson |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1821251422 PECOS PAC ID: 7911039276 Enrollment ID: I20100722000033 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Alana L Keller |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1558526301 PECOS PAC ID: 4284766544 Enrollment ID: I20100722000043 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Megan L Crowell |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1295966927 PECOS PAC ID: 9032241179 Enrollment ID: I20100726000014 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | James D Hollmann |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1578533410 PECOS PAC ID: 9032242722 Enrollment ID: I20100802000598 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Leah N Mathews |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1043407711 PECOS PAC ID: 0446331078 Enrollment ID: I20100823000869 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Daniel P Walsh |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1275536849 PECOS PAC ID: 1557485448 Enrollment ID: I20100830000410 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Tina M Dunkin |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1831401991 PECOS PAC ID: 6103941380 Enrollment ID: I20100910000840 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Theodore K. Sullivan |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1437153772 PECOS PAC ID: 3971628017 Enrollment ID: I20100914000260 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | James P Scherman |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1548574775 PECOS PAC ID: 7517082191 Enrollment ID: I20100920000846 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Steven Tilley |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1699766014 PECOS PAC ID: 5294722138 Enrollment ID: I20100928001106 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Marisa A Obrien |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1124332234 PECOS PAC ID: 8022201508 Enrollment ID: I20101015000829 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Todd Bellamy |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1093711137 PECOS PAC ID: 4981885373 Enrollment ID: I20110217000565 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Jerry Kassel |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1306842398 PECOS PAC ID: 0840471165 Enrollment ID: I20110221000130 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | James Wachter |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1689670697 PECOS PAC ID: 3779692678 Enrollment ID: I20110221000147 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Stephen Menzel |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1063418051 PECOS PAC ID: 6800077124 Enrollment ID: I20110221000183 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Glen Lojka |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1912903907 PECOS PAC ID: 0244411569 Enrollment ID: I20110221000197 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Raymond F Fada |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1013913094 PECOS PAC ID: 7214043801 Enrollment ID: I20110304000702 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Jeanine Dalton |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1780680868 PECOS PAC ID: 9739361288 Enrollment ID: I20110304000724 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Tuyet K Doan |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1578569653 PECOS PAC ID: 0547442097 Enrollment ID: I20110304000740 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Michael D Rohde |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1023014024 PECOS PAC ID: 9335321884 Enrollment ID: I20110304000771 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Amber Karpel |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1033115019 PECOS PAC ID: 5799967246 Enrollment ID: I20110304000777 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Margaret Deltergo-wachter |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1770589855 PECOS PAC ID: 2961684766 Enrollment ID: I20110316000198 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Henry Allhoff |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1942206107 PECOS PAC ID: 7517075450 Enrollment ID: I20110316000247 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Colleen C Shear |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1437155439 PECOS PAC ID: 4789867656 Enrollment ID: I20110330000835 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Leon M Romaine |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1922004928 PECOS PAC ID: 0446435119 Enrollment ID: I20110421000666 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Ernest C Doiron |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1558458521 PECOS PAC ID: 4183718406 Enrollment ID: I20110707000153 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Michael J Isserman |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1538165519 PECOS PAC ID: 0648448969 Enrollment ID: I20110712000438 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Eliot G Masek |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1134432149 PECOS PAC ID: 2466645312 Enrollment ID: I20120508000117 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Kayli M Schwamb |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1669750121 PECOS PAC ID: 1850548272 Enrollment ID: I20120820001017 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Gretchen A Gerhardt |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1831327857 PECOS PAC ID: 0244487940 Enrollment ID: I20120831000500 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Jeffrey James Lant |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1710241583 PECOS PAC ID: 9931357852 Enrollment ID: I20120919000316 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Sonia Salas |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1114254281 PECOS PAC ID: 1254475171 Enrollment ID: I20121001000169 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Matthew C Schwamb |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1609130434 PECOS PAC ID: 7012166051 Enrollment ID: I20121005000552 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Sameh A Boules |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1669648374 PECOS PAC ID: 6305902115 Enrollment ID: I20130124000465 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Lisa R Thatch |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1548210032 PECOS PAC ID: 8325178189 Enrollment ID: I20130521000658 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Mark A Wilkins |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1538423769 PECOS PAC ID: 7012156987 Enrollment ID: I20130625000823 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Andrea R Chancey |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1164861530 PECOS PAC ID: 1658512785 Enrollment ID: I20130801000068 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Stephanie L Cullinan |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1275898173 PECOS PAC ID: 2567696594 Enrollment ID: I20131007001224 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Neil F David |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1760815948 PECOS PAC ID: 2062648280 Enrollment ID: I20131118001772 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Stephanie C Long |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1639588965 PECOS PAC ID: 4385865419 Enrollment ID: I20141014002366 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Jessica L Laffoon |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1679980858 PECOS PAC ID: 0446471254 Enrollment ID: I20141021000113 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Melissa K Lorber |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1023373396 PECOS PAC ID: 9032435664 Enrollment ID: I20150226000113 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Fyizza Abbas |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1386053254 PECOS PAC ID: 9133447485 Enrollment ID: I20150416001044 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Sarah N Gore |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1871922369 PECOS PAC ID: 6507184777 Enrollment ID: I20150420001099 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Stephen Bollinger |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1003296120 PECOS PAC ID: 3072828987 Enrollment ID: I20150820010602 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Lindsay Schad |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1215312913 PECOS PAC ID: 2163737099 Enrollment ID: I20150820011319 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Andrew D Brown |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1104209220 PECOS PAC ID: 4880909605 Enrollment ID: I20150821014169 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Cortney M Fogarty |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1629451935 PECOS PAC ID: 5991011744 Enrollment ID: I20150825004109 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Shannon Niere |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1538510094 PECOS PAC ID: 5193010056 Enrollment ID: I20160817001706 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Parker S Berg |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1477968329 PECOS PAC ID: 0345541975 Enrollment ID: I20161004001840 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Sarah B Hirsch |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1003977232 PECOS PAC ID: 6204116908 Enrollment ID: I20161215002212 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Alexandra Schuette Homann |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1114351921 PECOS PAC ID: 1557597689 Enrollment ID: I20161230001716 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Alex Amann |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1942740212 PECOS PAC ID: 3678858958 Enrollment ID: I20170329000771 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Ashley S Hemphill |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1255851812 PECOS PAC ID: 5193096048 Enrollment ID: I20170810002049 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Kristen M Buskirk |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1720494412 PECOS PAC ID: 7315264728 Enrollment ID: I20170824000010 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Grant Hill |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1831440577 PECOS PAC ID: 3870733967 Enrollment ID: I20170908002300 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Leslie Marie Falch |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1770744625 PECOS PAC ID: 3779735485 Enrollment ID: I20180214000625 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Cailyn Katsev Ruck |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1093232456 PECOS PAC ID: 2961766159 Enrollment ID: I20180516002305 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Victoria Stewart |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1871087817 PECOS PAC ID: 1153679717 Enrollment ID: I20180730003591 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Judy Y Chun |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1356419006 PECOS PAC ID: 1557433851 Enrollment ID: I20180827003552 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Robert D. Sullivan |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1043799844 PECOS PAC ID: 9537419270 Enrollment ID: I20180830001386 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Rachel Rexing-thacker |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1437641354 PECOS PAC ID: 3274887328 Enrollment ID: I20181108002259 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Senija Turan |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1306378450 PECOS PAC ID: 4789952797 Enrollment ID: I20190405002115 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Lauren A Hansen |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1285049767 PECOS PAC ID: 2163642257 Enrollment ID: I20190718000302 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Dustin William Anderson |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1821640517 PECOS PAC ID: 3476889544 Enrollment ID: I20190726001140 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Karla R Hafford |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1548660517 PECOS PAC ID: 2365664950 Enrollment ID: I20200204001656 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Aric Waltz |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1609491422 PECOS PAC ID: 9032530498 Enrollment ID: I20200610003500 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Annie Nguyen |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1073136479 PECOS PAC ID: 9537581673 Enrollment ID: I20200618003179 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Robert William Duncan |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1700402500 PECOS PAC ID: 6204258213 Enrollment ID: I20200622000183 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Amanda Adkisson |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1275150906 PECOS PAC ID: 6204250475 Enrollment ID: I20200721002054 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Fei Fu |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1265039143 PECOS PAC ID: 7810317088 Enrollment ID: I20201009001518 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Nicholas Portell |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1851916035 PECOS PAC ID: 3870902844 Enrollment ID: I20210503002133 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Quinn Phillips Gallen |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1619594470 PECOS PAC ID: 5395151559 Enrollment ID: I20210519002749 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Lizabeth Marquart |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1356910913 PECOS PAC ID: 0244631760 Enrollment ID: I20210622001330 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Sabina M Hoover |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1922459528 PECOS PAC ID: 3971897893 Enrollment ID: I20220520002022 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Mohammed Salman |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1225760200 PECOS PAC ID: 0244610913 Enrollment ID: I20220712002345 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Ashley Lynn Dimercurio |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1871228551 PECOS PAC ID: 2062894355 Enrollment ID: I20220803001476 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Theresa Wang |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1881021186 PECOS PAC ID: 2163746397 Enrollment ID: I20221007001004 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Antonio Campbell |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1912107905 PECOS PAC ID: 5698926012 Enrollment ID: I20221007001609 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Paige Blankenheim |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1386361319 PECOS PAC ID: 5294102836 Enrollment ID: I20221110001179 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Alan Barber |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1841318839 PECOS PAC ID: 4183761588 Enrollment ID: I20230509000348 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Tyler Wayne Mathenia |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1033895131 PECOS PAC ID: 5799147203 Enrollment ID: I20230816000728 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Jacob Austin Travis |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1639863392 PECOS PAC ID: 7911369244 Enrollment ID: I20230817002153 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Jonathan Michael Klunk |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1306546916 PECOS PAC ID: 5092178780 Enrollment ID: I20231227000278 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Provider Name | Michelle Pearle Morrison |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1831899350 PECOS PAC ID: 6901257963 Enrollment ID: I20240104000906 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Clarkson Optometry, Inc Po Box 207158, Dallas, TX 75320-7158 Ph: (636) 200-4393 | Clarkson Optometry, Inc 217 Clarkson Rd, Ellisville, MO 63011-2219 Ph: (636) 200-4393 |
News Archive
Researchers have developed a potential new drug for the treatment of Polycystic kidney disease (PKD) – a deadly genetic condition affecting the kidneys that leads to formation of swellings or cysts within the kidney that cause it to fail.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 7 days ago
Melissa Kay Lorber, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 194 Clarkson Rd, Ellisville, MO 63011 Phone: 636-227-2020 | |
Dr. Jennifer Klinger, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 194 Clarkson Rd, Ellisville, MO 63011 Phone: 636-227-2020 Fax: 636-227-9968 | |
Dr. Gary Wayne Delancey, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 113 Old State Rd, Suite 101, Ellisville, MO 63021 Phone: 636-256-7800 Fax: 636-394-1011 | |
Optimized Eyecare, Llc Optometrist Medicare: Medicare Enrolled Practice Location: 317 Clarkson Rd, Ellisville, MO 63011 Phone: 314-374-6831 | |
Cusumano Vision Center, Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 317 Clarkson Rd, Ellisville, MO 63011 Phone: 636-391-3937 | |
Dr. James Wachter, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 194 Clarkson Rd, Ellisville, MO 63011 Phone: 636-227-2020 Fax: 636-227-9968 |